Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients - predictors of recurrence and survival

Breast

Volumn 24, Issue 4, 2015, Pages 384-390

  Rezai, M ^a   Kellersmann, S ^a,b   Knispel, S ^a,b   Lax, H ^b   Kimmig, R ^b   Kern, P ^a,b  

^a Breast Center Düsseldorf Luisenkrankenhaus   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Breast cancer; Intrinsic subtype; Margins; Recurrence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUESTIONNAIRE; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR LOCALIZATION; VERY ELDERLY; AXILLA; BREAST NEOPLASMS; CHEMISTRY; CLASSIFICATION; DECISION SUPPORT SYSTEM; EPIDEMIOLOGY; LYMPH NODE; LYMPH NODE DISSECTION; MORTALITY; PATHOLOGY; REGISTER; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MAMMAPLASTY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; REGISTRIES; SURVEYS AND QUESTIONNAIRES;

EID: 84930763881     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.02.030     Document Type: Article

References (25)

1. Sørlie T., Peroua C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U. S. A 2001, 98:10869-10874.
2. Morrow M., Harris J.R. More mastectomies: is this what patients really want?. JClin Oncol 2009, 27:4038-4040. Monica Morrow.
3. Kreienberg R., Jonat W., Möbus V., Kühn T. Mammakarzinom Interdisziplinär; 4. Auflage 2010, 84-85. Springer Verlag, Berlin, Heidelberg, New York.
4. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
5. AGO e.V. Guidlines Breast Version Oktober 2006; . http://www.ago-online.de.
6. Hammond M.E., Hayes D.F., Wolff A.C. Clinical notice for American society of clinical oncology-college of American pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. JClin Oncol 2011, 29:458.
7. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J. Panel Members: strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol 2011, 22:1736-1747.
8. Center for Cancer registry data, GEKID. Cancer in Germany, 2007/2008 2012, 64-67. Robert Koch-Institute and Society of epidemiological registry of cancer. 8th ed.
9. Miles R.C., Gullerud R.E., Lohse C.M., Jakub J.W., Degnim A.C., Boughey J.C. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol 2012, 19:1153-1159.
10. Kim H.J., Han W., Yi O.V., Shin H.C., Ahn S.K., Koh B.S., et al. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Res Treat 2011, 130:499-505.
11. Kim E.K., Noh W.C., Han W., Noh D.Y. Prognostic significance of young age (<35 Years) by subtype based on ER, PR, and HER2 status in breast Cancer: a nationwide registry-based study. World J Surg 2011, 35:1244-1253.
12. Han W., Kang S.Y. The Korean breast cancer society: relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010, 119:193-200.
13. Loibl S., Jackisch C., Gade S., Untch M., Paepke S., Kümmel S., et al. Neoadjuvant chemotherapy in the very young breast cancer patients. San Antonio breast cancer symposium 2013, for the GBG and AGO-B study groups.
14. Rausei S., Rovera F., Dionigi G., Tornese D., Fachinetti A., Boni L., Dionigi R. Predictors of loco-regional recurrence and cancer-related death after breast cancer surgery. Breast J 2010, 16:29-33.
15. Botteri E., Bagnardi V., Rotmensz N., Gentilini O., Disalvatore D., Bazolli B., et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 2010, 21:723-728.
16. Wapnir I.L., Anderson S.J., Mamounas E.P., Geyer C.E., Jeong J.H., Tan-Chiu E., et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. JClin Oncol 2006, 24:2028-2037.
17. Hernandez-Aya L.F., Chavez-MacGregor M., Lei X., Meric-Bernstam F., Buchholz T.A., Hsu L., et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. JClin Oncol 2011, 29:2628-2634.
18. Schwartz Arnold M., Earl Henson Donald, Chen Dechang, Rajamarthandan Sivasankari Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER program. Archives Pathology Laboratory Med August 2014, 138(No. 8):1048-1052.
19. Hattangadi-Gluth J.A., Wo J.Y., Nguyen P.L., Abi Raad R.F., Sreedhara M., Niemierko A., Freer P.E., Georgian-Smith D., Bellon J.R., Wong J.S., Smith B.L., Harris J.R., Taghian A.G. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys 2012, 82:1185-1191.
20. Wang Y., Yin Q., Yu Q., Zhang J., Liu Z., Wang S., et al. Aretrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 2011, 130:489-498.
21. Kern P., Rezai M., et al. Triple-Negative breast Cancer: prognosis of triple-negative breast cancer and non-triple-negative breast cancers in a large registry of certified breast units. San Antonio breast cancer symposium 2012, [P2-10-14].
22. Jones T., Neboori H., Wu H., Yang Q., Haffty B.G., Evans S., et al. Are breast cancer subtypes prognostic for nodal involvement and associated with clinico-pathologic features at presentation in early-stage breast cancer?. Ann Surg Oncol 2013 Sep, 20(9):2866-2872.
23. Arpino G., Bardou V.J., Clark G.M., Elledge R.M. Infiltrating lobular carcinoma of the breast:tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6:149-156.
24. Lee H.L., Park S., Park H.S., Park B.W. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol 2010, 8:34.
25. Pestalozzi B.C., Zahrieh D., Mallon E., Gusterson B.A., Price K.N., Gelber R.D., et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. JClin Oncol 2008, 26:3006-3030.